DBV Technologies S.A. (DBVT) Stock

DBV Technologies S.A., a clinical-stage biopharmaceutical company headquartered in Montrouge, France, specializes in the development of epicutaneous immunotherapy products aimed at treating food allergies and other immune-related disorders. The company's flagship product candidate, Viaskin Peanut, has completed Phase III clinical trials and targets the treatment of peanut allergies in children aged 4 to 11 years, adolescents, and adults. DBV Technologies is also advancing Viaskin Milk through Phase I/II clinical trials for Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA), and has a pre-clinical stage product, Viaskin Egg, in development for hen's egg allergy.

Beyond its food allergy focus, DBV Technologies is actively engaged in several earlier stage research initiatives. These include a vaccine for Bordetella pertussis, commonly known as whooping cough, and ongoing research programs exploring potential treatments for respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. The company collaborates with Nestle Health Science to develop MAG1C, an atopy patch test designed to diagnose non-IgE mediated CMPA in infants and toddlers, underscoring its commitment to advancing diagnostic capabilities alongside therapeutic innovations.

Founded in 2002, DBV Technologies has established itself as a leader in the field of epicutaneous immunotherapy, leveraging its expertise to address significant unmet medical needs in allergy management. With a robust pipeline and strategic collaborations, DBV Technologies continues to pursue groundbreaking solutions that aim to improve the quality of life for patients affected by food allergies and related conditions worldwide.